---
title: "RemeGen rises sharply in intraday trade to HKD83.20"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292149626.md"
description: "RemeGen (9995.HK) surged during regular trading to HKD83.20, despite a slight overall decline of 0.12% for the day."
datetime: "2026-07-09T05:10:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292149626.md)
  - [en](https://longbridge.com/en/news/292149626.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292149626.md)
generator: "portal-rs"
---

# RemeGen rises sharply in intraday trade to HKD83.20

RemeGen (9995.HK) **surged** during regular trading to **HKD83.20**. The stock posted a slight overall decline of **0.12%** for the session, with the sharp intraday move representing normal volatility.

No clear catalyst was identified.

### Related Stocks

- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)

## Related News & Research

- [RemeGen Shareholders Back All Resolutions at 2025 AGM](https://longbridge.com/en/news/289949552.md)
- [J.P. Morgan Reaffirms Their Buy Rating on RemeGen Co. Ltd. Class H (9995)](https://longbridge.com/en/news/295287684.md)
- [Higgsfield raises $400 million in Series B at $5.4 billion valuation, Intel Capital joins round](https://longbridge.com/en/news/296370991.md)
- [Ascentage Pharma posts interim results presentation on 1H 2026 business update](https://longbridge.com/en/news/296418315.md)
- [Aikobio’s AK0406 flu prevention drug wins China IND clearance for clinical trials](https://longbridge.com/en/news/296204995.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**